Welcome to our dedicated page for Moolec Science SA SEC filings (Ticker: MLECW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Moolec Science SA files as a foreign private issuer, and its regulatory documents disclose the business, governance, and capital structure of a science-based food ingredient company focused on scalable protein solutions. Its Form 6-K reports and related exhibits cover annual general meeting materials, consolidated financial statements, board composition, registration-statement incorporation, and shareholder voting matters.
The filings also document completed capital-structure and control developments, including preference-share conversion into ordinary shares and the emergence of a controlling shareholder. Other disclosures address Nasdaq listing compliance, a completed reverse stock split, Form 20-F reporting, S-8 registration context, and governance practices applicable to the company’s public securities.
Moolec Science SA reports that it has regained compliance with all Nasdaq Capital Market continued listing requirements. A Nasdaq Hearings Panel confirmed that the company now meets rules on timely financial reporting, minimum bid price, and minimum stockholders’ equity that were previously cited as deficiencies.
The Panel has imposed a one-year discretionary monitoring period, and Moolec will also be under a mandatory panel monitor for one year relating to its financial reporting and stockholders’ equity requirements. The company plans to keep monitoring its status but cautions there is no assurance it will maintain compliance in the future.
Moolec Science SA reports that it has regained compliance with all Nasdaq Capital Market continued listing requirements. A Nasdaq Hearings Panel confirmed that the company now meets rules on timely financial reporting, minimum bid price, and minimum stockholders’ equity that were previously cited as deficiencies.
The Panel has imposed a one-year discretionary monitoring period, and Moolec will also be under a mandatory panel monitor for one year relating to its financial reporting and stockholders’ equity requirements. The company plans to keep monitoring its status but cautions there is no assurance it will maintain compliance in the future.
Moolec Science SA reported the results of its virtual annual general meeting of shareholders held on May 13, 2026. Shareholders representing 1,482,096 ordinary shares out of 2,080,437 entitled to vote, or 71.240%, were present, satisfying quorum requirements.
Investors approved the consolidated financial statements for the financial year ended June 30, 2025. They also re-elected directors Diego Abelleyra Llodra, Oscar Leon Bentancor, Romualdo Varela, and Daniel Core for terms lasting until the next annual general meeting or until successors are appointed.
Shareholders further approved the re-appointment of Price Waterhouse & Co. S.R.L. as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2026. All three resolutions passed as ordinary resolutions by more than a simple majority of votes cast.
Moolec Science SA reported the results of its virtual annual general meeting of shareholders held on May 13, 2026. Shareholders representing 1,482,096 ordinary shares out of 2,080,437 entitled to vote, or 71.240%, were present, satisfying quorum requirements.
Investors approved the consolidated financial statements for the financial year ended June 30, 2025. They also re-elected directors Diego Abelleyra Llodra, Oscar Leon Bentancor, Romualdo Varela, and Daniel Core for terms lasting until the next annual general meeting or until successors are appointed.
Shareholders further approved the re-appointment of Price Waterhouse & Co. S.R.L. as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2026. All three resolutions passed as ordinary resolutions by more than a simple majority of votes cast.
Moolec Science reports that it has regained compliance with all Nasdaq Capital Market continued listing requirements related to the minimum stockholders’ equity standard within the remediation period granted by the Nasdaq Hearings Panel. The company reported stockholders’ equity of approximately $15.2 million as of March 31, 2026 and $11.3 million as of December 31, 2025.
An equity-strengthening step was the partial conversion of preference shares, with ordinary shares valued at $5,473,425 recorded as equity as of December 31, 2025. Moolec’s preliminary March 31, 2026 balance sheet shows total assets around $104 million, including $71.6 million of intangible assets and $16.0 million in investments in joint ventures and associates, alongside borrowings and convertible notes totaling over $70 million.
The company also reflects a pro forma adjustment for $465,161 drawn under a related-party credit line in April 2026 and states that it expects to request conversion of the remaining $4.0 million of preference shares within the next 12 months, which it indicates is expected to further strengthen stockholders’ equity.
Moolec Science reports that it has regained compliance with all Nasdaq Capital Market continued listing requirements related to the minimum stockholders’ equity standard within the remediation period granted by the Nasdaq Hearings Panel. The company reported stockholders’ equity of approximately $15.2 million as of March 31, 2026 and $11.3 million as of December 31, 2025.
An equity-strengthening step was the partial conversion of preference shares, with ordinary shares valued at $5,473,425 recorded as equity as of December 31, 2025. Moolec’s preliminary March 31, 2026 balance sheet shows total assets around $104 million, including $71.6 million of intangible assets and $16.0 million in investments in joint ventures and associates, alongside borrowings and convertible notes totaling over $70 million.
The company also reflects a pro forma adjustment for $465,161 drawn under a related-party credit line in April 2026 and states that it expects to request conversion of the remaining $4.0 million of preference shares within the next 12 months, which it indicates is expected to further strengthen stockholders’ equity.
Moolec Science filed a Form 6-K to share the notice of its virtual Annual General Meeting of shareholders. The AGM will be held on May 13, 2026 at 9:00 a.m. Eastern Time.
Shareholders will vote on three proposals: approval of the consolidated financial statements for the year ended June 30, 2025, re-election of four directors (Daniel Core, Diego Abelleyra Llodra, Oscar Leon Bentancor and Romualdo Varela), and re-appointment of Price Waterhouse & Co. S.R.L. as independent registered public accounting firm for the fiscal year ending June 30, 2026.
Holders of shares as of the April 6, 2026 record date are eligible to vote, primarily by submitting proxies by May 11, 2026 at 11:59 p.m. Eastern time. The meeting will be conducted virtually via a dedicated hosting page with telephone listen-only access.
Moolec Science filed a Form 6-K to share the notice of its virtual Annual General Meeting of shareholders. The AGM will be held on May 13, 2026 at 9:00 a.m. Eastern Time.
Shareholders will vote on three proposals: approval of the consolidated financial statements for the year ended June 30, 2025, re-election of four directors (Daniel Core, Diego Abelleyra Llodra, Oscar Leon Bentancor and Romualdo Varela), and re-appointment of Price Waterhouse & Co. S.R.L. as independent registered public accounting firm for the fiscal year ending June 30, 2026.
Holders of shares as of the April 6, 2026 record date are eligible to vote, primarily by submitting proxies by May 11, 2026 at 11:59 p.m. Eastern time. The meeting will be conducted virtually via a dedicated hosting page with telephone listen-only access.
Moolec Science SA director Daniel Joaquin Core filed a Form 3 reporting existing equity awards rather than any new share purchases or sales. He reports direct holdings of options over 934 ordinary shares at an exercise price of $7.14 expiring on June 30, 2031, plus separate option holdings over 933 shares expiring on June 30, 2032 and another 933 shares expiring on June 30, 2033.
Moolec Science SA director Daniel Joaquin Core filed a Form 3 reporting existing equity awards rather than any new share purchases or sales. He reports direct holdings of options over 934 ordinary shares at an exercise price of $7.14 expiring on June 30, 2031, plus separate option holdings over 933 shares expiring on June 30, 2032 and another 933 shares expiring on June 30, 2033.
Agriculture Investment Group Corp. became the controlling shareholder of Moolec Science SA by converting preference shares into ordinary shares. It now beneficially owns 1,354,186 ordinary shares, representing 65.1% of Moolec’s outstanding ordinary shares. Total ordinary shares outstanding were 2,080,304 as of January 5, 2026.
The conversion followed a $5,473,425 aggregate amount of preference shares being exchanged for ordinary shares under a Subscription Agreement originally dated December 9, 2024 and later amended. Agriculture Investment Group now has sole voting and dispositive power over its entire Moolec stake.
Agriculture Investment Group Corp. became the controlling shareholder of Moolec Science SA by converting preference shares into ordinary shares. It now beneficially owns 1,354,186 ordinary shares, representing 65.1% of Moolec’s outstanding ordinary shares. Total ordinary shares outstanding were 2,080,304 as of January 5, 2026.
The conversion followed a $5,473,425 aggregate amount of preference shares being exchanged for ordinary shares under a Subscription Agreement originally dated December 9, 2024 and later amended. Agriculture Investment Group now has sole voting and dispositive power over its entire Moolec stake.
Agriculture Investment Group Corp. became the controlling shareholder of Moolec Science SA, reporting beneficial ownership of 1,354,186 ordinary shares, or 65.1% of the company, after converting preference shares into ordinary shares under a prior subscription agreement.
The ownership percentage is based on 2,080,304 ordinary shares outstanding as of January 5, 2026. Agriculture Investment Group Corp. holds sole voting and dispositive power over its shares and states it may review and change its intentions toward Moolec Science over time.
Agriculture Investment Group Corp. became the controlling shareholder of Moolec Science SA, reporting beneficial ownership of 1,354,186 ordinary shares, or 65.1% of the company, after converting preference shares into ordinary shares under a prior subscription agreement.
The ownership percentage is based on 2,080,304 ordinary shares outstanding as of January 5, 2026. Agriculture Investment Group Corp. holds sole voting and dispositive power over its shares and states it may review and change its intentions toward Moolec Science over time.
Moolec Science reports a change in control after Agriculture Investment Group Corp. (AIGC) became its controlling shareholder. On April 1, 2026, AIGC held 65.1% of Moolec’s outstanding shares following a partial conversion of its preference shares into ordinary shares under an existing subscription agreement. As a foreign private issuer, Moolec has chosen to follow home country practice instead of Nasdaq’s usual requirement for prior shareholder approval in transactions that result in a change of control.
Moolec Science reports a change in control after Agriculture Investment Group Corp. (AIGC) became its controlling shareholder. On April 1, 2026, AIGC held 65.1% of Moolec’s outstanding shares following a partial conversion of its preference shares into ordinary shares under an existing subscription agreement. As a foreign private issuer, Moolec has chosen to follow home country practice instead of Nasdaq’s usual requirement for prior shareholder approval in transactions that result in a change of control.
Moolec Science SA Chief Financial Officer Valeria Ines Falottico filed an initial insider ownership report listing her holdings in the company’s ordinary shares and equity awards. She directly holds 891 ordinary shares.
The filing also lists share options over 2,222 ordinary shares at an exercise price of $7.14 per share, with expiration dates in 2031, 2032, and 2033. In addition, she holds restricted share unit awards linked to 2,333 underlying ordinary shares at $14.28 per share and 2,333 underlying ordinary shares at $28.56 per share, both expiring in 2031.
Moolec Science SA Chief Financial Officer Valeria Ines Falottico filed an initial insider ownership report listing her holdings in the company’s ordinary shares and equity awards. She directly holds 891 ordinary shares.
The filing also lists share options over 2,222 ordinary shares at an exercise price of $7.14 per share, with expiration dates in 2031, 2032, and 2033. In addition, she holds restricted share unit awards linked to 2,333 underlying ordinary shares at $14.28 per share and 2,333 underlying ordinary shares at $28.56 per share, both expiring in 2031.
Moolec Science SA director Lorenzo Varela has filed a Form 3 reporting his initial beneficial ownership in the company. The filing shows three direct option-based positions over ordinary shares, each with a $7.14 exercise price and expirations in 2031, 2032, and 2033.
The underlying options cover 934, 933, and 933 ordinary shares, respectively, and are structured as share options rather than open-market share purchases or sales. The disclosure is administrative, establishing his baseline holdings without reporting any new buy or sell transactions.
Moolec Science SA director Lorenzo Varela has filed a Form 3 reporting his initial beneficial ownership in the company. The filing shows three direct option-based positions over ordinary shares, each with a $7.14 exercise price and expirations in 2031, 2032, and 2033.
The underlying options cover 934, 933, and 933 ordinary shares, respectively, and are structured as share options rather than open-market share purchases or sales. The disclosure is administrative, establishing his baseline holdings without reporting any new buy or sell transactions.